MedPath

Efficacy of Parecoxib on Patients With CRPS

Conditions
Causalgia
Registration Number
NCT01523379
Lead Sponsor
Ruhr University of Bochum
Brief Summary

The complex regional pain syndrom is a weighty disease that often results in a lifelong disability. Mostly this disease appears unilateral after comparatively mundane fractures or operations. In early stages CRPS shows inflammatory processes. These inflammatory components can be seen as edema and vasodilatation. These inflammatory processes lead us to the hypothesis that selective COX-2-inhibitors might help patients with CRPS.

Detailed Description

Not available

Recruitment & Eligibility

Status
NO_LONGER_AVAILABLE
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Patients with saved diagnosis of CRPS of the upper extremity based on the current used criteria for diagnosis plus a positiv 3-phase-sceletal-scintilgraphy, if they show pathological PPT-values in QST on the ipsilateral site (Z-values > 2 in age- and gender-based Z-transformation of the raw values)• age ≥ 18 years• Existence of an age-based normal creatinin-clearance (calculated with a defined formula)
Exclusion Criteria
  • Important cardiovascular illness for the purpose of heart failure (NYHA II - IV), coronary heart disease (CHD), peripheral artery occlusive disease (PAOD) or unstable hypertension (values constantly over 140/90 mm Hg)

    • Florid kidney disease

    • Cerebral disease

    • Neurological systemic disorder (exception: beginning polyneuropathy with normal values of the PPT on the opposite side)

    • Lesion of the median nerve (ipsi- oder contralateral)

    • Acute bleeding disease

    • Known ulcer of the stomach or duodenum

    • Inflammatory bowel disease

    • Positive anamnesis of a gastrointestinal bleeding in the last 5 years

    • Important hepatic dysfunction (Child- pugh > 9)

    • Hypersensitivity to the agent or to sulfonamides

    • Known allergy to acetylsalicylic acid, nonsteroidal antiinflammatory drugs or other selectiv cyclooxygenase-inhibitors

    • Pregnancy and lactation period

    • Intake of one of the following drugs (current or in the last 3 days)

      • selective-serotonin-reuptake-inhibitor
      • cetoconazole
      • rifampicin
      • phenytoin
      • carbamazepine
      • dexamethasone or other systemic corticoids
      • traditional nonsteroidal antiphlogistics
      • cyclooxygenase-inhibitors
      • immunsupressives
      • TNF-α-inhibitors

Study & Design

Study Type
EXPANDED_ACCESS
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath